{"id":"W2761129333","doi":"10.1007/s11060-017-2624-4","title":"Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02","year":2017,"lang":"en","type":"article","venue":"Journal of Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ontario Institute for Cancer Research; Public Health Ontario","funders":"National Cancer Institute; National Institutes of Health","keywords":"Sorafenib; Medicine; Internal medicine; Oncology; Toxicity; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001449802,0.001363856,0.00208722,0.0005175343,0.0004845141,0.001467675,0.001513995,0.001253571,0.003559245],"category_scores_gemma":[0.0009927101,0.0007777957,0.001691434,0.0005168301,0.001007545,0.0008715952,0.0004114547,0.003791047,0.001426157],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001747025,"about_ca_system_score_gemma":0.003184728,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004204845,"about_ca_topic_score_gemma":0.01292724,"domain_scores_codex":[0.9995695,0.000177588,0.00002299369,0.00006137852,0.00004719767,0.0001213454],"domain_scores_gemma":[0.9992675,0.00007517372,0.00009268703,0.00006388958,0.0000623382,0.0004383964],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6179482,0.08838173,0.009591038,0.001294907,0.003763468,0.0005150061,0.0006792314,0.007069037,0.05118835,0.0009507922,0.01810319,0.2005149],"study_design_scores_gemma":[0.5554903,0.4159896,0.01004109,0.00005433612,0.001198649,0.0007263134,0.0002129587,0.003492661,0.00481485,0.0004352666,0.007467036,0.00007710393],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934203,0.001536819,0.0003363886,0.0005686685,0.0001698507,0.001097526,0.001099654,0.0001324158,0.001638467],"genre_scores_gemma":[0.9873068,0.00196409,0.001523394,0.0008867424,0.0001167607,0.001473529,0.002987938,0.00005986102,0.003680951],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004204845,"threshold_uncertainty_score":0.01267564,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05229702977251907,"score_gpt":0.3962628312140511,"score_spread":0.3439658014415321,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}